Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

A new study shows low rates of pre-exposure prophylaxis (PrEP) prescribing to sexual and gender minority individuals living ...

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and b ...

Seventy percent of Asian American and Pacific Islander women diagnosed with lung cancer were non- or never-smokers, ...